Abstract
The development of progressive renal dysfunction is indeed a frequent complication in heart failure (HF) and represents the consequence of the combined effects of progressive decay in cardiac output and renal perfusion pressure, in conjunction with excess renal vasoconstriction. In fact, factors predisposing the development of HF such as ageing, hypertension, and myocardial ischemia are also frequently accompanied by a diminished renal function. Frequently, the degree and impact of renal dysfunction and its impact on outcomes in patients with HF are often underdiagnosed and underestimated. This is especially relevant considering that a decreased renal function is associated with a significant increment in mortality in HF. Several evidences have demonstrated the efficacy of renin–angiotensin–aldosterone blockade as a relevant component of HF treatment. However, the benefits of HF therapy do not come without some risk, and hyperkalemia is a frequent finding, especially in presence of renal dysfunction. We will review the participation of the kidney in HF and the renal consequences of the treatment, with special emphasis on the risk of hyperkalemia and its management in daily clinical practice.
Originally published in Bakris, The Kidney in Heart Failure, ISBN: 978-1-4614-3693-5
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
US Department of Health and Human Services. Heart failure: evaluation and care of patients with left ventricular systolic dysfunction. Clinical Practice Guidelines no. 11, AHCPR publication no. 94-0612, June 1994.
Kannel WB, Ho K, Thom T. Changing epidemiological features of cardiac failure. Br Heart J. 1994;72 Suppl 2:S3–9.
Cohn JN. The management of chronic heart failure. N Engl J Med. 1996;335:490–8.
Sica DA, Hess M. Pharmacotherapy in congestive heart therapy: aldosterone receptor antagonism: interface with hyperkalemia in heart failure. Congest Heart Fail. 2004;10:259–64.
Lindeman RD, Tobin JD, Shock NW. Association between blood pressure and the rate of decline in renal function with age. Kidney Int. 1984;26:861–8.
Ruilope LM, Lahera V, Rodicio JL, Romero JC. Are renal hemodynamics a key factor in the development and maintenance of essential hypertension? Hypertension. 1994;23:3–9.
Eijkelkamp WB, de Graeff PA, van Veldhuisen DJ, et al. Prevention of Renal and Vascular End-Stage Disease (PREVEND) Study Group. Effect of first myocardial ischemic event on renal function. Am J Cardiol. 2007;100:7–12.
Muntner P, Coresh J, Powe NR, Klag MJ. The contribution of increased diabetes prevalence and improved myocardial infarction and stroke survival to the increase in treated end-stage renal disease. J Am Soc Nephrol. 2003;14:1568–77.
Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139:137–47.
Heywood JT, Fonarow GC, Costanzo MR, Mathur VS, Wigneswaran JR, Wynne J, for the ADHERE scientific advisory committee and investigators. High prevalence of renal dysfuncion and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Cardiac Fail. 2007;13:422–30.
Ljungman S, Kjekshus J, Swedberg K, for the Consensus Trial Group. Renal function in severe congestive heart failure during treatment with enalapril. Am J Cardiol. 1992;70:479–87.
Hillege HL, Girbes AR, de Kam PJ, et al. Renal function, neurohumoral activation and survival in patients with chronic heart failure. Circulation. 2000;102:203–10.
Shulman NB, Ford CE, Hall WD, et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. Hypertension. 1989;13(Suppl I):I80–93.
Ruilope LM, Campo C, Rodriguez-Artalejo F, Lahera V, Garcia-Robles R, Rodicio JL. Blood pressure and renal function: therapeutic implications. J Hypertens. 1996;14:1259–63.
Ruilope LM, Salvetti A, Jamerson K, et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J Am Soc Nephrol. 2001;12:218–25.
Culleton BF, Larson MG, Wilson PWF, Evans JC, Parfrey PS, Levy D. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int. 1999;56:2214–9.
Ruilope LM, Barrios V, Volpe M. Renal implications of the renin-angiotensin-aldosterone system blockade in heart failure. J Hypertens. 2000;18:1545–51.
Anand IS, Bishu K, Rector TS, Ishani A, Kuskowski MA, Cohn JN. Proteinuria, chronic kidney disease and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure. Circulation. 2009;120:1577–84.
DeFronzo RA, Sherwin RS, Felig P, et al. Nonuremic diabetic hyperkalemia: possible role of insulin deficiency. Arch Intern Med. 1977;137:842–3.
Bratusch-Marrain PR, DeFronzo RA. Impairment of insulin-mediated glucose metabolism by hyperosmolarity in man. Diabetes. 1983;32:1028–34.
Rosa RM, Silva P, Young JB, et al. Adrenergic modulation of extrarenal potassium disposal. N Engl J Med. 1980;302:431–4.
Kurtzman NA, Gonzalez J, DeFronzo R, et al. A patient with hyperkalemia and metabolic acidosis. Am J Kidney Dis. 1990;15:333–56.
Cody RJ, Ljungman S, Covit AB, et al. Regulation of glomerular filtration rate in chronic congestive heart failure patients. Kidney Int. 1988;34:361–7.
Obialo CI, Ofili EO, Mirza T. Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease. Am J Cardiol. 2002;90:663–5.
Lawson DH, O’Connor PC, Jick H. Drug attributed alterations in potassium handling in congestive cardiac failure. Eur J Clin Pharmacol. 1982;23:21–5.
Bakris GL, Siomos M, Richardson D, et al. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. Kidney Int. 2000;58:2084–92.
The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429–35.
The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293–302.
The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685–91.
de Denus S, Tardif JC, White M, et al. Quantification of the risk and predictors of hyperkalemia in patients with left ventricular dysfunction: a retrospective analysis of the Studies of Left Ventricular Dysfunction (SOLVD) trials. Am Heart J. 2006;152:705–12.
Dickstein K, Kjekshus J, for the OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: The OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet. 2002;360:752–60.
Cohn JN, Tognoni G, for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667–75.
Pfeffer MA, Sweberg K, Granger CB, et al. CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362:759–66.
McMurray JJ, Ostergren J, Swedberg K, et al. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function treated with an ACE inhibitor: the CHARM-Added trial. Lancet. 2003;362:767–71.
Granger CB, McMurray JJ, Yusuf S, et al. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function and intolerant to ACE inhibitors: the CHARM-Alternative trial. Lancet. 2003;362:772–6.
Yusuf S, Pfeffer MA, Swedberg K, et al. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left ventricular systolic function: the CHARM-Preserved trial. Lancet. 2003;362:777–81.
Desai AS, Swedberg K, McMurray JJV, et al. Incidence and predictors of hyperkalemia in patients with heart failure. J Am Coll Cardiol. 2007;50:1959–66.
Cohen-Solal A, McMurray JJV, Swedberg K, et al. Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity programme. Eur Heart J. 2008;29:3022–8.
Dzau VJ, Sasamura H, Hein L. Heterogeneity of angiotensin synthetic pathways and receptor subtypes—physiological and pharmacological implications. J Hypertens. 1993;11:S13–8.
Konstam MA, Neaton JD, Dickstein K, et al., for the HEAAL Investigators. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet. 2009;374:1840–8.
Phillips CO, Kashani A, Ko DK, Francis G, Krumholz HMK. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction. Arch Intern Med. 2007;167:1930–6.
Pfeffer MA, McMurray JJ, Velazquez EJ, et al., for the Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both [published correction appears in N Engl J Med. 2004;350:203]. N Engl J Med. 2003;349:1893–1906.
Hunt SA, Abraham WT, Chin MH, et al. American College of Cardiology. American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Rhythm Society. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005;112: e154–235.
Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med. 2000;160:685–93.
Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709–17.
Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351:543–51.
Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–21. Erratum in: N Engl J. 2003;348:2271.
Staessen JA, Li Y, Richart T. Oral renin inhibitors. Lancet. 2006;368:1449–56.
Birkenhager WH, Staessen JA. Dual inhibition of the renin system by aliskiren and valsartan. Lancet. 2007;370:195–6.
Seed A, Gardner R, McMurray J, et al. Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure. Eur J Heart Fail. 2007;9:1120–7.
McMurray JJV, Pitt B, Latini R, et al., for the Aliskiren Observation of Heart Failure Treatment (ALOFT) Investigators. Circ Heart Fail. 2008;1:17–24.
Gehr TWB, Sica DA. Hyperkalemia in congestive heart failure. Congest Heart Fail. 2001;7:97–100.
Shah KB, Rao K, Sawyer R, Gottlieb SS. The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure. J Am Coll Cardiol. 2005;46:845–9.
Vanpee D, Swine CH. Elderly heart failure patients with drug-induced serious hyperkalemia. Aging. 2000;12:315–9.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media New York
About this chapter
Cite this chapter
Segura, J., Ruilope, L.M. (2012). Hyperkalemia Risk and Treatment of Heart Failure. In: Bakris, G. (eds) Managing the Kidney when the Heart is Failing. Springer, Boston, MA. https://doi.org/10.1007/978-1-4614-3691-1_3
Download citation
DOI: https://doi.org/10.1007/978-1-4614-3691-1_3
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4614-3690-4
Online ISBN: 978-1-4614-3691-1
eBook Packages: MedicineMedicine (R0)